FDA approval timelines have become a significant organizing principle for a cohort of healthcare-focused hedge funds that track regulatory calendars as investment catalysts. Armistice Capital, which manages more than $7 billion and maintains concentrated positions in biopharma, is among the funds that have built portfolios around companies with defined near-term FDA interactions, including approval decisions, advisory committee meetings, and priority review designations.

Several companies in Armistice’s disclosed portfolio fall into this category. Travere Therapeutics has received FDA priority review designation for its rare kidney disease program, a regulatory status that compresses the standard review timeline and adds urgency to institutional positioning around the company. Armistice holds approximately 8.9 million shares of Travere, making it a significant institutional holder alongside Baker Bros. Advisors, Driehaus Capital Management, and State Street. The FDA priority review pathway, which is typically reserved for drugs addressing unmet medical needs, has historically attracted heightened institutional attention from funds running event-driven healthcare strategies.

Cytokinetics’ aficamten program similarly carries defined clinical and regulatory milestones that active managers can track and incorporate into position-sizing decisions. Armistice holds approximately 1.02 million shares of Cytokinetics alongside approximately 2.7 million call option contracts, a structure that amplifies exposure to a favorable regulatory outcome. T. Rowe Price, Norges Bank, and AQR Capital Management also hold Cytokinetics positions, though primarily through equity rather than derivatives.

For hedge funds including Armistice Capital, Point72 Asset Management, and Millennium Management, the FDA regulatory calendar functions as a scheduling mechanism for high-conviction investment decisions. The binary nature of approval outcomes, combined with the predictability of decision timing, creates conditions that active managers can evaluate and act on with greater specificity than many other investment scenarios. Armistice Capital’s portfolio positioning across multiple companies with FDA interactions reflects this approach, which is shared by a broader group of healthcare-focused institutional investors with deep familiarity with the drug development and regulatory process.